Cyclopharm

Cyclopharm Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Cyclopharm (CYC.AX) as of Nov 12, 2026 is 100.64 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 95.28 % — a change of 5.62% (higher).

Cash Conversion

100.64 %

YoY

5.62%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Cyclopharm is 2025 100.64 % . Cash Conversion Rate (OCF/Net Income) of Cyclopharm was 2024 95.28 % . It decreases by 5.62% higher compared to the previous year.

The Cyclopharm Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
3,123.12 AUD
Jan 1, 2019
16.80 AUD
Jan 1, 2020
147.84 AUD
Jan 1, 2021
32.33 AUD
Jan 1, 2022
85.91 AUD
Jan 1, 2023
153.11 AUD
Jan 1, 2024
95.28 AUD
Jan 1, 2025
100.64 AUD
The Cyclopharm Cash Conversion history
YEARCash ConversionYoY
100.64 %+5.62%
95.28 %-37.77%
153.11 %+78.22%
85.91 %+165.74%
32.33 %-78.13%
147.84 %+779.91%
16.80 %-99.46%
3,123.12 %+6,880.32%
44.74 %-39.09%
73.46 %-15.26%
86.68 %-21.14%
109.92 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cyclopharm Stock analysis

What does Cyclopharm do? Cyclopharm Ltd is an Australian company that was founded in 1986 and has since been developing innovative medical solutions. The company operates in the field of nuclear medicine and focuses on providing diagnostic and therapeutic products and services. The history of Cyclopharm Ltd began with the development of the Technetium-99m generator, an instrument for generating radioisotopes that can be used in medical imaging. Since then, the company has expanded its offerings and now offers a wide range of products and services. Cyclopharm Ltd's business model is based on research and development of new solutions based on the needs of the medical community and patients. The company works closely with doctors, scientists, and other experts to ensure that its products and services meet the highest standards. Cyclopharm Ltd is divided into various divisions to coordinate and optimize its activities. These include diagnostics, therapy, research and development, as well as sales and marketing. Each division works closely with the others to ensure that the company achieves its goals and provides optimal customer care. Some of Cyclopharm Ltd's most well-known products include the Technetium-99m generator and the radiopharmaceutical Technegas. Technegas is a gas used for lung imaging and plays an important role in diagnosing lung problems. The radiopharmaceutical is produced using the Technetium-99m generator and is an important addition to medical imaging. In addition, Cyclopharm Ltd also develops therapeutic solutions that can be used to treat cancer and other diseases. These include radiopharmaceuticals used in radiation therapy, as well as other solutions tailored to the individual needs of patients. Cyclopharm Ltd is also actively working on improving and expanding its products and services. The company invests in research and development to develop innovative solutions that can improve medical imaging and therapy. Additionally, the company works closely with its customers to better understand their needs and offer them tailored solutions. Overall, Cyclopharm Ltd is an innovative and goal-oriented company that focuses on providing diagnostic and therapeutic solutions in the field of nuclear medicine. The company has a long history of leadership in this field and will continue to be at the forefront of developing solutions that improve the lives of patients and medical professionals. Cyclopharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cyclopharm stock

Cash Conversion Rate (OCF/Net Income) of Cyclopharm is 100.64 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Cyclopharm changed from 95.28 % to 100.64 %, representing a 5.62% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Cyclopharm since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Cyclopharm with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Cyclopharm

All Key Metrics — Cyclopharm